Crescent Grove Advisors’s Xtant Medical Holdings XTNT Stock Holding History

Crescent Grove Advisors’s Portfolio XTNT Stock Details XTNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Hold	412,024	–	–	0.01%	294
2026 Q1	$230K	Hold	412,024	–	–	0.02%	269
2025 Q4	$323K	Hold	412,024	–	–	0.03%	229
2025 Q3	$267K	Hold	412,024	–	–	0.03%	252
2025 Q2	$304K	Buy	412,024 +200,000	+94%	+$114K	0.03%	215
2025 Q1	$99.7K	Hold	212,024	–	–	0.01%	257
2024 Q4	$93.9K	Hold	212,024	–	–	0.01%	272
2024 Q3	$143K	Hold	212,024	–	–	0.01%	271
2024 Q2	$134K	Hold	212,024	–	–	0.01%	271
2024 Q1	$248K	Hold	212,024	–	–	0.03%	269
2023 Q4	$240K	Hold	212,024	–	–	0.03%	259
2023 Q3	$233K	Sell	212,024 -50,000	-19%	-$53.7K	0.03%	250
2023 Q2	$244K	Hold	262,024	–	–	0.03%	253
2023 Q1	$167K	Hold	262,024	–	–	0.02%	277
2022 Q4	$173K	Hold	262,024	–	–	0.02%	266
2022 Q3	$189K	Hold	262,024	–	–	0.02%	247
2022 Q2	$136K	Buy	262,024 +100,000	+62%	+$59.2K	0.01%	254
2022 Q1	$110K	Hold	162,024	–	–	0.01%	288
2021 Q4	$91K	Buy	+162,024	New	+$153K	0.01%	288

Other funds holding XTNT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Crescent Grove Advisors's XTNT Position: Q2 2026 in Review

Crescent Grove Advisors held its Xtant Medical Holdings (XTNT) position steady in Q2 2026 at 412,024 shares worth $173K. The position accounts for 0.01% of the portfolio, ranked #294.

Crescent Grove Advisors first reported a position in XTNT in Q4 2021 and has held it in 19 quarters since. The position peaked at $323K in Q4 2025. 32 funds tracked by Wall St. Rank hold XTNT as of Q2 2026.

Crescent Grove Advisors held 412,024 shares of Xtant Medical Holdings worth $173K as of Q2 2026.
Crescent Grove Advisors left its Xtant Medical Holdings share count unchanged in Q2 2026.
Xtant Medical Holdings made up 0.01% of Crescent Grove Advisors's portfolio in Q2 2026, its #294 holding.
Crescent Grove Advisors first reported a position in Xtant Medical Holdings in Q4 2021 and has held it in 19 quarters since.
Crescent Grove Advisors's Xtant Medical Holdings position peaked at $323K in Q4 2025.
32 funds tracked by Wall St. Rank held Xtant Medical Holdings as of Q2 2026.

Based on Crescent Grove Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.